Karin Oechsle1, Michael Hartmann2, Anja Mehnert3,4, Christoph Oing5, Carsten Bokemeyer5, Sigrun Vehling3. 1. Department of Oncology, Hematology and Bone Marrow Transplantation with Section of Pneumology, University Medical Center Hamburg-Eppendorf, Martinistr. 52, 20246, Hamburg, Germany. k.oechsle@uke.de. 2. Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. 3. Department of Medical Psychology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. 4. Division of Psychosocial Oncology, Department of Medical Psychology and Medical Sociology, University Medical Center Leipzig, Leipzig, Germany. 5. Department of Oncology, Hematology and Bone Marrow Transplantation with Section of Pneumology, University Medical Center Hamburg-Eppendorf, Martinistr. 52, 20246, Hamburg, Germany.
Abstract
PURPOSE: Testicular germ cell tumor (GCT) and its treatment may cause distressing long-term symptoms. We aimed to examine self-reported symptom frequency and distress as well as the impact of demographic and medical characteristics in GCT survivors. METHODS: A total of 164 GCT survivors receiving follow-up care at the University Cancer Center Hamburg and a specialized private practice facility were interviewed at a median time of 11.6 years after first diagnosis. Metastatic disease was present in 48 % of the patients and relapse had occurred in 17 %. The patients completed the short form of the Memorial Symptom Assessment Scale (MSAS-SF) assessing 28 physical and 4 psychological symptoms. RESULTS: The mean number of physical symptoms was 4.5 (SD = 4.3) (psychological symptoms M = 1.4, SD = 1.4; total M = 5.9, SD = 5.2). The most frequent physical symptoms were lack of energy (49 %), feeling drowsy (42 %), sleeping problems (36 %), and difficulty in concentration (32 %). Lack of energy was experienced as highly distressing by 21 % of the patients. The most frequent psychological symptoms were irritability (47 %) and being worried (42 %). The number of physical symptoms was associated with higher age, lower socioeconomic status, and shorter time since diagnosis in multivariate regression analyses controlling for metastatic vs. localized disease, relapse, extent of surgery, number of chemotherapy cycles, and radiotherapy. CONCLUSIONS: GCT survivors suffered from a significant number of long-term symptoms. Fatigue-related symptoms were most frequent and perceived as highly distressing. Continuous attention toward fatigue is necessary throughout follow-up care to offer support in time, particularly in more vulnerable patients of higher age and lower socioeconomic status.
PURPOSE: Testicular germ cell tumor (GCT) and its treatment may cause distressing long-term symptoms. We aimed to examine self-reported symptom frequency and distress as well as the impact of demographic and medical characteristics in GCT survivors. METHODS: A total of 164 GCT survivors receiving follow-up care at the University Cancer Center Hamburg and a specialized private practice facility were interviewed at a median time of 11.6 years after first diagnosis. Metastatic disease was present in 48 % of the patients and relapse had occurred in 17 %. The patients completed the short form of the Memorial Symptom Assessment Scale (MSAS-SF) assessing 28 physical and 4 psychological symptoms. RESULTS: The mean number of physical symptoms was 4.5 (SD = 4.3) (psychological symptoms M = 1.4, SD = 1.4; total M = 5.9, SD = 5.2). The most frequent physical symptoms were lack of energy (49 %), feeling drowsy (42 %), sleeping problems (36 %), and difficulty in concentration (32 %). Lack of energy was experienced as highly distressing by 21 % of the patients. The most frequent psychological symptoms were irritability (47 %) and being worried (42 %). The number of physical symptoms was associated with higher age, lower socioeconomic status, and shorter time since diagnosis in multivariate regression analyses controlling for metastatic vs. localized disease, relapse, extent of surgery, number of chemotherapy cycles, and radiotherapy. CONCLUSIONS: GCT survivors suffered from a significant number of long-term symptoms. Fatigue-related symptoms were most frequent and perceived as highly distressing. Continuous attention toward fatigue is necessary throughout follow-up care to offer support in time, particularly in more vulnerable patients of higher age and lower socioeconomic status.
Entities:
Keywords:
Distress; Germ cell tumor; Survivor; Symptom burden; Testicular cancer
Authors: Joke Fleer; Dirk T Sleijfer; Harald J Hoekstra; Marrit A Tuinman; Josette E H M Hoekstra-Weebers Journal: Anticancer Res Date: 2005 Nov-Dec Impact factor: 2.480
Authors: Robert Abouassaly; Sophie D Fossa; Aleksander Giwercman; Christian Kollmannsberger; Robert J Motzer; Hans-Joachim Schmoll; Cora N Sternberg Journal: Eur Urol Date: 2011-06-12 Impact factor: 20.096
Authors: Jakob Eberhard; Olof Ståhl; Gabriella Cohn-Cedermark; Eva Cavallin-Ståhl; Yvonne Giwercman; Lars Rylander; Malin Eberhard-Gran; Ulrik Kvist; Kerstin S Fugl-Meyer; Aleksander Giwercman Journal: J Sex Med Date: 2009-04-28 Impact factor: 3.802
Authors: Hege S Haugnes; George J Bosl; Hink Boer; Jourik A Gietema; Marianne Brydøy; Jan Oldenburg; Alv A Dahl; Roy M Bremnes; Sophie D Fosså Journal: J Clin Oncol Date: 2012-09-24 Impact factor: 44.544
Authors: Ingrid J Orre; Sophie D Fosså; Robert Murison; Roy Bremnes; Olav Dahl; Olbjørn Klepp; Jon H Loge; Erik Wist; Alv A Dahl Journal: J Psychosom Res Date: 2008-04 Impact factor: 3.006
Authors: Sanne B Schagen; Willem Boogerd; Martin J Muller; Wim Ten Bokkel Huinink; Luc Moonen; Wim Meinhardt; Frits S A M Van Dam Journal: Acta Oncol Date: 2008 Impact factor: 4.089
Authors: Noa Shani Shrem; Lori Wood; Robert J Hamilton; Kopika Kuhathaas; Piotr Czaykowski; Matthew Roberts; Andrew Matthew; Jason P Izard; Peter Chung; Lucia Nappi; Jennifer Jones; Denis Soulières; Armen Aprikian; Nicholas Power; Christina Canil Journal: Can Urol Assoc J Date: 2022-08 Impact factor: 2.052
Authors: Scott C Adams; Darren S DeLorey; Margie H Davenport; Adrian S Fairey; Scott North; Kerry S Courneya Journal: Br J Cancer Date: 2018-05-08 Impact factor: 7.640